id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-002846-la9svzml	Strohl, William R.	Current progress in innovative engineered antibodies	2017-08-18		.txt	text/plain	13114	605	43	The second most targeted protein is CD3E, found in 32 clinical stage or approved molecules, of which 26 are T cell-redirecting bispecific antibody candidates (Table 6) . For example, 10 of them bind two soluble antigens such as IL13 and IL4 (e.g., SAR156597; NCT02345070), nine bind two receptors on the , IgG-scFv fusion, Mabtyrin (IgG with non-antibody binding scaffold "centyrin" fused to C-terminal end of heavy chains); (C) IgGs to which additional antigen combining sites have been added within the structure (e.g., two-in-one antibodies, MAT "Modular Antibody Technology" platform from F-Star); (D) Engineered antibody fragments linked by short peptide linkers which can be made into bivalent, trivalent, or tetravalent formats addressing two to three targets (e.g., bispecific T-cell engager (BiTE), Nanobody platform, dual-affinity re-targeting (DART) antibodies, "tandem antibody" structures (TandAbs)); (E) Chemically coupled IgGs. Brennan et al., 1985; Garrido et al., 1990 Innovative antibodies Mack et al., 1995; Schlereth et al., 2005; Baeuerle et al., 2008 TandAb Antibody fragmentWilliam R.	./cache/cord-002846-la9svzml.txt	./txt/cord-002846-la9svzml.txt